跳至主要内容
临床试验/ChiCTR-INC-16009306
ChiCTR-INC-16009306进行中(未招募)治疗新技术临床试验

褪黑素联合 DHEA 治疗卵巢储备功能下降的临床试验

中南大学湘雅医院生殖医学中心1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2016年9月25日最近更新:

试验速览

阶段
治疗新技术临床试验
状态
进行中(未招募)
发起方
入组人数
200
试验地点
1
主要终点
Embryological outcomes

研究概览

简要总结

The aim of the study is whether oral melatonin plus DHEA administration can improve the outcome of IVF in Diminished Ovarian Reserve (DOR) patients as follows: To determine embryological outcome; To determine biochemical outcome (to find out optimum hormono-microfollicular enviroment for high quality oocyte through comparing Melatonin, Estrogen, Progestrogen and LH in follicular fluidin leading follicles of different group patients including PCOS, Normal Ovarian Reserve, DOR patients with or without Melatonin plus DHEA treated).

研究设计

研究类型
干预性研究
主要目的
横断面

入排标准

年龄范围
20 至 52(—)
性别
Female

入选标准

  • For DOR patient:
  • The criteria for DOR included AMH, FSH and Estradiol (E2) levels as well as antral follicle counts (AFC) or retrieved oocyte number. The patients were considered to have DOR if they have had serum AMH levels ≤ 1 ng/ml or an AFC≤5 on Day 3 of a spontaneous cycle or retrieved oocyte number ≤
  • For NOR patient (Normal Ovarian Reserve):
  • The criteria for Normal Ovarian Reserve (NOR) patients included AMH>3 ng/ml, FSH≤10 IU/ml, an AFC≥8 and or retrieved oocyte number ≥
  • For PCOS patient:
  • The criteria for PCOS patients included AMH>10 ng/ml, FSH/LH ratio >2, AFC for each ovaries ≥ 12(Total ≥ 25) and or retrieved oocyte number ≥ 15 or clinical and/or biochemical signs of hyperandrogenism.

排除标准

  • The patients with known conditions affecting ovarian reserve, including ovarian surgery, polycystic ovarian syndrome, endometriosis, post chemo and radiation therapy recovery or BMI ≥ 25 will be excluded.

研究组 & 干预措施

1(随机分组)

Daily melatonin dosage is 4 mg capsule orally, take at 22:00–23:00 pm, in accordance with the studies of Tamura et al. and Simpson et al. Administration of melatonin will begin from the 5th day of the Menstrual cycle until the human chorionic gonadotropin (hCG) injection day of the controlled ovarian

2(随机分组)

without treatment

3(不参与随机分组)

without treatment

4(不参与随机分组)

without treatment

结局指标

主要结局

Embryological outcomes

时间窗: oocyte quality, fertilization rate and embryo quality for each patients

次要结局

  • 生化指标(Melatonin, LH, Estrogen, Progesterone levels in follicular fluid in leading follicle at the time of oocyte collection)

研究者

发起方
中南大学湘雅医院生殖医学中心

研究点 (1)

Loading locations...

相似试验